Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2020-09-04 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Prochains rendez-vous investisseurs
Investor Presentation Classification · 95% confidence The document is titled "PROCHAINS RENDEZ-VOUS INVESTISSEURS" (Upcoming Investor Meetings) and announces the company's participation in several virtual investor conferences (Citi's BioPharma Conference, Goldman Sachs Symposium, H.C. Wainwright Conference) scheduled for September 2020. It provides a brief company overview, contact information, and standard forward-looking statements. This type of announcement, detailing planned investor engagement events rather than releasing periodic financial results (ER/IR) or official regulatory reports (10-K/AR), is best classified as a general communication aimed at investors. Since there is no specific category for 'Investor Event Schedule Announcement,' and it is a formal communication about company activities, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, although 'Investor Presentation' (IP) is related, this document is an announcement *about* attending events, not the presentation itself. Given the context of investor relations communication, RNS is the most appropriate fallback for this type of scheduling notice.
2020-09-04 French
Upcoming investor conferences
Regulatory Filings Classification · 99% confidence The document is a press release dated September 4, 2020, announcing the Company's plan to participate in several upcoming virtual investor conferences in September 2020 (Citi's 15th Annual BioPharma Virtual Conference, Goldman Sachs 10th Annual Biotech Symposium 2020, H.C. Wainwright 22nd Annual Global Investment Conference). It also contains standard company information, forward-looking statements, and contact details. This type of announcement, detailing participation in investor events, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or more generally, a communication aimed at investors regarding corporate activities. Since it is an announcement about *upcoming* investor events and general company updates, it fits best under the Investor Presentation (IP) category, as these announcements often precede or accompany investor outreach efforts, or it could be a general Regulatory Filing (RNS). Given the focus on specific investor conferences, IP is a strong candidate, but since it is not a presentation document itself, but rather an announcement *about* participation, it is more accurately a general corporate communication. However, looking at the definitions, none perfectly capture 'Investor Conference Schedule Announcement'. It is not an Earnings Release (ER), nor a Management Discussion (MDA). Since it is a formal communication to investors about corporate outreach, and given the options, it is closest to an Investor Presentation (IP) contextually, or a general Regulatory Filing (RNS). Given the content is purely informational about future events and company background, and not a specific financial report or mandatory filing like 10-K or DIV, RNS is the safest fallback. However, if we interpret 'Investor Presentation' broadly to include communications surrounding investor engagement, IP might be intended. Let's re-evaluate based on the 'Menu vs Meal' rule. This is a short announcement (4806 chars) about future events, not a detailed report. It is not announcing the publication of a major report. Therefore, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for this type of corporate news release that doesn't fit the specific financial report codes.
2020-09-04 English
FORM 6-K
Regulatory Filings
2020-08-12 English
Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er août 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER AOUT 2020" (New number of shares and voting rights as of August 1, 2020). It explicitly states that it is published in accordance with French Commercial Code articles and AMF regulations (Autorité des marchés financiers) to disclose the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the capital structure and voting power, often required monthly or quarterly by regulators like the AMF, fits best under the category related to share capital changes or major shareholding notifications. Since it details the total number of shares and voting rights, it is a direct announcement concerning the share structure. The closest fit among the provided codes is 'SHA' (Share Issue/Capital Change) or potentially 'MRQ' (Major Shareholding Notification) if interpreted broadly, but 'SHA' directly relates to the number of shares comprising the capital. Given the context of mandatory regulatory disclosure of the total share count, SHA is the most appropriate classification.
2020-08-12 French
FORM 6-K
Regulatory Filings
2020-08-11 English
Innate Pharma obtient un financement public de 6,8M€ pour ses activités de recherche et développement dans la COVID-19
Capital/Financing Update Classification · 98% confidence The document is a press release dated August 11, 2020, announcing that Innate Pharma obtained a €6.8M public financing grant from Bpifrance (under the PSPC-COVID call) to support its COVID-19 R&D activities. This announcement details a specific corporate financing event (receiving government funds/grant) and its immediate impact on R&D programs. This fits the definition of 'Capital/Financing Update' (CAP) better than a general 'Regulatory Filing' (RNS), as it is a specific announcement about capital structure/funding, even if it's a grant rather than debt/equity issuance. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a specific announcement about securing funding, CAP is the most appropriate code.
2020-08-11 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.